(1) Superficial infections
... cell wall of susceptible filamentous fungi that is absent in mammalian cells. • Echinocandins are available only as parenteral formulations • adverse effects of echinocandins include histamine release resulting in rash, facial swelling, and itchiness. ...
... cell wall of susceptible filamentous fungi that is absent in mammalian cells. • Echinocandins are available only as parenteral formulations • adverse effects of echinocandins include histamine release resulting in rash, facial swelling, and itchiness. ...
Prescription practice in patients of upper respiratory tract infection at
... across India has been reported by Dimri et. al. and Shankar et. al. as 45% & 68%, respectively.13,14 The prescribing from NLEM in the later study was higher which was carried out at a public hospital setting. The prescribing from the NLEM should be promoted for optimal use of financial resources and ...
... across India has been reported by Dimri et. al. and Shankar et. al. as 45% & 68%, respectively.13,14 The prescribing from NLEM in the later study was higher which was carried out at a public hospital setting. The prescribing from the NLEM should be promoted for optimal use of financial resources and ...
Exelon - DavisPlus
... anorexia, or weight loss occur. If adverse effects become intolerable during treatment with transdermal patch, instruct patient to discontinue patches for several days and then restart at same or next lower dose level. If treatment is interrupted for more than several days, lowest dose level should ...
... anorexia, or weight loss occur. If adverse effects become intolerable during treatment with transdermal patch, instruct patient to discontinue patches for several days and then restart at same or next lower dose level. If treatment is interrupted for more than several days, lowest dose level should ...
Product Monograph - Sanofi Genzyme Canada
... AUBAGIO. Further monitoring should be based on signs and symptoms suggestive of infection. In any situation in which the decision is made to switch to or from AUBAGIO, from or to another agent with a known potential for hematologic suppression, monitoring for hematologic toxicity is recommended, bec ...
... AUBAGIO. Further monitoring should be based on signs and symptoms suggestive of infection. In any situation in which the decision is made to switch to or from AUBAGIO, from or to another agent with a known potential for hematologic suppression, monitoring for hematologic toxicity is recommended, bec ...
Parkinson Meds
... Medication: levodopa Adverse: nausea, vomiting, orthostatic hypotednsion dystonic movements, anorexia, dysphagia, chorieform movements, On off effect= long term use of the drug may have an irregulr response to the drug….. Reduce the maintanence dose and substitute another anti parkinson’s drug ...
... Medication: levodopa Adverse: nausea, vomiting, orthostatic hypotednsion dystonic movements, anorexia, dysphagia, chorieform movements, On off effect= long term use of the drug may have an irregulr response to the drug….. Reduce the maintanence dose and substitute another anti parkinson’s drug ...
A STUDY OF ADVERSE DRUG REACTIONS IN PATIENTS ADMITTED TO... OF A TERTIARY CARE TEACHING RURAL HOSPITAL
... of a drug. Inspite of these, under-reporting of the adverse drug reactions remains a major draw-back. It is estimated that only 6– 10% of all ADRs are reported. In some of the developing countries it might be very difficult to attribute the adverse reactions to a particular drug. This may be due to ...
... of a drug. Inspite of these, under-reporting of the adverse drug reactions remains a major draw-back. It is estimated that only 6– 10% of all ADRs are reported. In some of the developing countries it might be very difficult to attribute the adverse reactions to a particular drug. This may be due to ...
oral direct thrombin inhibitors
... These drugs inhibit factor Xa, in the final common pathway of clotting . These drugs are given as fixed doses and do not require monitoring. They have a rapid onset of action and shorter half-lives than warfarin (approximately 10 hours but half-life may be prolonged in elderly patients or those with ...
... These drugs inhibit factor Xa, in the final common pathway of clotting . These drugs are given as fixed doses and do not require monitoring. They have a rapid onset of action and shorter half-lives than warfarin (approximately 10 hours but half-life may be prolonged in elderly patients or those with ...
PDR® entry for Naphcon-A Ophthalmic Solution (Alcon)
... lactating women. Therefore, OCUREST/OCUREST-AH should only be used if clearly indicated. ...
... lactating women. Therefore, OCUREST/OCUREST-AH should only be used if clearly indicated. ...
Finlepsin 200 tablets 200 mg 1
... Treatment is started with a low dose set individually according to the type and severity of symptoms. The dose is then slowly increased to the optimal maintenance dose to suit the patient. Doses should be established from plasma level measurements in particular, if combination therapy is used. When ...
... Treatment is started with a low dose set individually according to the type and severity of symptoms. The dose is then slowly increased to the optimal maintenance dose to suit the patient. Doses should be established from plasma level measurements in particular, if combination therapy is used. When ...
Drug Therapy in Pediatric Patients
... • Infants especially sensitive to drugs that affect CNS function • Dosage should also be reduced for drugs used for actions outside the CNS if those drugs are capable of producing CNS toxicity as a side effect – Endogenous compounds compete with drugs for available binding sites • Limited drug/prote ...
... • Infants especially sensitive to drugs that affect CNS function • Dosage should also be reduced for drugs used for actions outside the CNS if those drugs are capable of producing CNS toxicity as a side effect – Endogenous compounds compete with drugs for available binding sites • Limited drug/prote ...
SEDA - Elsevier
... A case history may be summarized (including the age and sex of the patient) if it provides a clear illustration of the type of case that the physician is likely to meet, or if it has unusual features. The description should be as brief as possible, including only those elements that appear to be rel ...
... A case history may be summarized (including the age and sex of the patient) if it provides a clear illustration of the type of case that the physician is likely to meet, or if it has unusual features. The description should be as brief as possible, including only those elements that appear to be rel ...
Seasonal Ocular Allergy: New Options for a Recurring Problem
... conjunctivitis, and about 95 percent of the cases of ocular allergy are seasonal or perennial in nature.1 The good news: More treatment options are available today than a decade ago, and many of the newer drugs require application only once a day, unlike the regimen of two or four times daily with t ...
... conjunctivitis, and about 95 percent of the cases of ocular allergy are seasonal or perennial in nature.1 The good news: More treatment options are available today than a decade ago, and many of the newer drugs require application only once a day, unlike the regimen of two or four times daily with t ...
Clorhidrato de Propafenona. Monografia del farmaco.
... impaired ventricular function (mean CI = 2.61 L/min/m2) utilizing IV propafenone infusions (2 mg/kg over 10 min + 2 mg/min for 30 min) that gave mean plasma concentrations of 3.0 μg/ml (well above the therapeutic range of 0.2-1.5 μg/ml) showed significant increases in pulmonary capillary wedge press ...
... impaired ventricular function (mean CI = 2.61 L/min/m2) utilizing IV propafenone infusions (2 mg/kg over 10 min + 2 mg/min for 30 min) that gave mean plasma concentrations of 3.0 μg/ml (well above the therapeutic range of 0.2-1.5 μg/ml) showed significant increases in pulmonary capillary wedge press ...
Current Management of Alzheimer’s Disease
... Corey-Bloom J et al. Int J Geriatr Psychopharmacol. 1998;1:55-65. ...
... Corey-Bloom J et al. Int J Geriatr Psychopharmacol. 1998;1:55-65. ...
Brodil Levo
... It is not known whether levosalbutamol is excreted in human milk. Caution should be exercised when oral levosalbutamol is administered to a nursing woman. Drug Interactions Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with levosalbutamol. If addition ...
... It is not known whether levosalbutamol is excreted in human milk. Caution should be exercised when oral levosalbutamol is administered to a nursing woman. Drug Interactions Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with levosalbutamol. If addition ...
MHRA Drug Safety Update - Royal College of Psychiatrists
... before, during, and immediately after the first 6 hours of treatment. If the patient’s heart rate decreases to its lowest point at the end of the 6-hour treatment period, monitoring should be extended until heart rate increases. Monitoring should also be extended at least overnight if significant at ...
... before, during, and immediately after the first 6 hours of treatment. If the patient’s heart rate decreases to its lowest point at the end of the 6-hour treatment period, monitoring should be extended until heart rate increases. Monitoring should also be extended at least overnight if significant at ...
here - Michael Rogawski
... providing a basis for the use of AMPA receptors in the treatment of epilepsy. Studies with early AMPA receptor antagonists in animal seizure models (4,5) and also the kindling model of epilepsy (6) demonstrated that selective blockade of AMPA receptors could represent a strategy to confer protection ...
... providing a basis for the use of AMPA receptors in the treatment of epilepsy. Studies with early AMPA receptor antagonists in animal seizure models (4,5) and also the kindling model of epilepsy (6) demonstrated that selective blockade of AMPA receptors could represent a strategy to confer protection ...
Reviewer 1 - WHO archives
... antihistamines should be avoided in porphyria, but some (e.g. chlorphenamine are thought to be safe . Sedating antihistamines should not be given to children under 2 years, except on specialist advice, because the safety of such use has not been established. Sedating antihistamines have significa ...
... antihistamines should be avoided in porphyria, but some (e.g. chlorphenamine are thought to be safe . Sedating antihistamines should not be given to children under 2 years, except on specialist advice, because the safety of such use has not been established. Sedating antihistamines have significa ...
February-March 2015 - Medical Arts Pharmacy
... duration possible and at failure when compared with the general population. Elderly patients are the lowest effective dose. also more likely to be taking more medications than a healthy adult and are more likely to be at risk from drug interactions with NSAIDs. Elderly individuals are generally at a ...
... duration possible and at failure when compared with the general population. Elderly patients are the lowest effective dose. also more likely to be taking more medications than a healthy adult and are more likely to be at risk from drug interactions with NSAIDs. Elderly individuals are generally at a ...
Thrombolytic Medications
... Patients with congenital coagulation deficiency Patients with thrombocytopenia Patients with hepatic or renal insufficiency ...
... Patients with congenital coagulation deficiency Patients with thrombocytopenia Patients with hepatic or renal insufficiency ...
Learn more about IC from Elmiron
... •• Additional resources such as IC-friendly recipes and stress and coping techniques are available through the following: ...
... •• Additional resources such as IC-friendly recipes and stress and coping techniques are available through the following: ...
July/August 2008, Number 7
... has a labeled indication for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Although not generally used as a first-line agent for osteoporosis, there are some clinical circumstances when nasal calcitoni ...
... has a labeled indication for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Although not generally used as a first-line agent for osteoporosis, there are some clinical circumstances when nasal calcitoni ...
Drugs for primary generalized epilepsy
... approved in 15 years. Although there was great initial enthusiasm for this agent, in less than a year post-marketing surveillance revealed an unacceptably high rate of drug-related aplastic anemia. Lamotrigine was approved in late 1994. It is thought to act by blockade of sodium channels; useful in ...
... approved in 15 years. Although there was great initial enthusiasm for this agent, in less than a year post-marketing surveillance revealed an unacceptably high rate of drug-related aplastic anemia. Lamotrigine was approved in late 1994. It is thought to act by blockade of sodium channels; useful in ...
IVF-Treatment-Fertility-Medications-and-Their-Side
... taking the medication; for example headaches or nausea. There are also “adverse effects.” These are more serious events, usually rare and often unpredictable. An example includes ovarian hyperstimulation syndrome (OHSS). Overall, fertility medications are generally safe and usually associated with o ...
... taking the medication; for example headaches or nausea. There are also “adverse effects.” These are more serious events, usually rare and often unpredictable. An example includes ovarian hyperstimulation syndrome (OHSS). Overall, fertility medications are generally safe and usually associated with o ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.